Based on Canada NDS PR, sounds like they are looking for a pretty broad label...
“The NDS seeks an indication for promotion of Vascepa in Canada to reduce the risk of major adverse cardiovascular events (“MACE”) in statin-treated patients with elevated triglycerides and other risk factors...if approved, Vascepa will be the first drug approved in Canada for this indication.”